Highlights of This Issue 845

REVIEW

847  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel and Razelle Kurzrock

SMALL MOLECULE THERAPEUTICS

857  Preclinical Pharmacological Evaluation of Letrozole as a Novel Treatment for Gliomas
Nimita Dave, Lionel M.L. Chow, Gary A. Gudelsky, Kathleen LaSance, Xiaoyang Qi, and Pankaj B. Desai

865  Functional Genetic Screen Identifies Increased Sensitivity to WEEl Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways
Marieke Aarts, Irljana Bajrami, Maria T. Herrera-Abreu, Richard Elliott, Rachel Brough, Alan Ashworth, Christopher J. Lord, and Nicholas C. Turner

877  ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells
Shu Wang, Xiangyun Amy Chen, Jing Hu, Jian-kang Jiang, Yunfei Li, Ka Yim Chan-Salis, Ying Gu, Gong Chen, Craig Thomas, B. Franklin Pugh, and Yanning Wang

889  The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias
Maria Vittoria Verga Falzacappa, Chiara Ronchini, Mario Faretra, Ilaria Iacobucci, Andrea Ghelli Lusena Di Rorà, Giovanni Martinelli, Ludin Hinrich Meyer, Klaus-Michael Debatin, Stefania Orecchioni, Francesco Bertolini, and Pier Giuseppe Pellici

909  IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment

920  Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA–Wild-Type Triple-Negative Breast Cancer

MAGNIFICATION

941  New Blocking Antibodies against Novel AGR2–C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice
Thinuvengadam Arumugam, Deleng Deng, Laura Bover, Huamin Wang, Craig D. Logsdon, and Vijaya Ramachandran
Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Frank Loganzo, Xingzhi Tan, Matthew Sung, Guixian Jin, Jeremy S. Myers, Eugene Melamud, Steven H. Young, Liang Han, James Simmet-Smith, and Enrique Rozengurt

Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody
John E. Leonard, Terrence L. Fisher, Laurie A. Winter, Chad A. Cornelius, Christine Reilly, Ernest S. Smith, and Maurice Zauderer

A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts
Marc A. Becker, Paul Haluska Jr, Laurie K. Bale, Claus Oxvig, and Cheryl A. Conover

The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis
Ni Wang, Roni F. Rayes, Seyyed Mehdy Elahi, Yifan Lu, Mark A. Hancock, Bernard Massie, Gerald E. Rowe, Hafida Aomari, Sazzad Hossain, Yves Durocher, Maxime Pinard, Sébastien Tabaries, Peter M. Siegel, and Pnina Brodt

Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
Helena P. Soares, Ming Ming, Michelle Mellion, Steven H. Young, Liang Han, James Simmet-Smith, and Enrique Rozengurt

Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma
Kyung Seok Han, Na Li, Peter A. Raven, Ladan Fazli, Susan Ettinger, Sung Joon Hong, Martin E. Gleave, and Alan I. So

Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth
Galina Gritsina, Fang Xiao, Shane W. O’Brien, Rashid Gabbasov, Marisa A. Maglaty, Ren-Huan Xu, Roshan J. Thapa, Yan Zhou, Emmanuelle Nicolas, Samuel Litwin, Siddhharth Balachandran, Luis J. Sigal, Dennis Huszar, and Denise C. Connolly

Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus
Yingmiao Liu, Mark D. Starr, John C. Brady, Christel Rushing, Anuradha Bulusu, Herbert Pang, Wanda Honeycutt, Anthony Amara, Ivy Altmare, Hope E. Uronis, Herbert I. Hurwitz, and Andrew B. Nixon

Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer
Arvind Arora, Tarek M.A. Abdel-Fatah, Devika Agarwal, Rachel Doherty, Paul M. Moseley, Mohammed A. Aleskandaramy, Andrew R. Green, Graham Ball, Alaa T. Alshareeda, Emad A. Rakha, Stephen Y.T. Chan, Ian O. Ellis, and Srinivasan Madhusudan
Polymorphic CAG Repeat and Protein Expression of Androgen Receptor Gene in Colorectal Cancer

Rui Huang, Guiyu Wang, Yanni Song, Feng Wang, Bing Zhu, Qingchao Tang, Zheng Liu, Yinggang Chen, Qian Zhang, Shan Muhammad, and Xishan Wang

Multifunctional Polymeric Micelles Co-loaded with Anti–Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer

Giuseppina Salzano, Gemma Navarro, Malav S. Trivedi, Giuseppe De Rosa, and Vladimir P. Torchilin

ABOUT THE COVER

Deregulation of cell-cycle checkpoints is a feature of many different cancer types. WEE1 kinase plays an important role in the maintenance of these cell-cycle checkpoints by inhibiting cyclin-dependent kinase (CDK) activity. Through siRNA screening, it was found that cancer cells with defects in Fanconi Anemia (FA) and homologous recombination pathways were more sensitive to WEE1 inhibition. The cover image shows that WEE1 inhibition in cells depleted of FA protein FANCM resulted in increased replication stress (pan-nuclear γH2AX staining in green) and premature entry into mitosis (yellow). Phospho-histone H3 staining (red) was used to identify mitotic cells. DNA was counterstained with DAPI (blue). For details, see the article by Aarts and colleagues on page 865.